GEN Exclusives

More »

GEN Poll

More »
Apr 24, 2012

Alzheimer Drugs

Few to no drugs have emerged that impact either the cause or progression of diseases of the central nervous system. Early- and late-stage drug failures, mostly with small molecule drugs and the odd peptide, populate the neurodegenerative disease landscape. Companies have moved away from these types of drugs toward biologics like mAb therapeutics. Those that can successfully develop novel treatments, despite the formidable obstacles to drug development, have a lot to gain. The global market for neurodegenerative treatments will exceed $43.4 billion by 2015, Global Industry Analysts predict. Do you think there will be a breakthrough with mAbs?

Do you believe mAb therapeutics will be the answer to treating Alzheimer disease?

Yes
 
  28.6%
No
 
  52.4%
Undecided
 
  19.0%

More Polls » View Results »

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?